ResMed Inc. (RMD) Heads into FY2027 With Margin Expansion, Strong Cash Flow, and a Bigger Dividend

Summary snapshot: solid quarter, robust full-year results, and a capital-return tilt

ResMed Inc. reported a fourth quarter and fiscal year 2026 that reinforced a narrative of margin expansion and cash-dominant growth. For the quarter, GAAP diluted EPS rose to $2.64, up 2% year over year, while non‑GAAP diluted EPS climbed 16% to $2.95. On the revenue line, Q4 sales reached $1.5 billion, a 9% increase from the prior year and an 8% gain on a constant‑currency basis. Full year results mirrored that momentum: FY2026 revenue of $5.7 billion, up 10% (8% CC).

The company’s profitability story is corroborated by margin improvements across the board. FY2026 GAAP gross margin rose to 61.1% (non‑GAAP 62.4%), while GAAP operating margin advanced 70 basis points to 33.4% and non‑GAAP operating margin rose 180 basis points to 36.1%. Free cash flow totaled $1.6 billion on $1.8 billion of operating cash flow, underscoring the company’s ability to translate earnings into shareholder-friendly capital deployment.

Outlook and capital-allocation discipline: a dividend boost and a big capital-return plan

The management signaled a sturdy capital-return trajectory for FY2027, guiding more than $1.85 billion to be returned to shareholders through a mix of share repurchases and dividends. In practical terms, ResMed announced a 10% dividend increase to $0.66 per quarter, a clear signal of confidence in ongoing cash generation and a commitment to rewarding investors even as the company pursues growth initiatives.

For investors and EPS consensus watchers, the headline numbers for FY2026—$10.43 GAAP and $11.17 non‑GAAP on a per‑share basis—translate into a meaningful step higher versus prior expectations, particularly when viewed alongside margins that imply durable profitability. The webcast note in the release—set for 4:30 p.m. ET—serves as a reminder that management is inviting questions on cadence, not just headline figures.

What stood out in the numbers

Revenue highlights for the year reflect a resilient mix and effective pricing discipline across markets. The fourth quarter’s top line of $1.5 billion came with a 9% year‑over‑year improvement, and the full year's revenue growth of 10% (8% CC) suggests ongoing demand for ResMed’s market-leading devices and related digital solutions.

The margin expansion is notable: GAAP gross margin up 170 basis points to 61.1% and non-GAAP gross margin up 240 basis points to 62.4%; GAAP operating margin up 70 basis points to 33.4% and non-GAAP operating margin up 180 basis points to 36.1%. This combination—growth with margin uplift—helps explain the strength in EPS both on a GAAP and non‑GAAP basis.

Cash generation remains a core strength: FY2026 operating cash flow was $1.8 billion, with free cash flow of $1.6 billion. The ability to convert earnings into cash supports the program to return capital and funds ongoing investments in innovation and market expansion.

Leadership commentary: leverage scale, digital, and patient-centric growth

In remarks from Chairman and CEO Mick Farrell, ResMed framed the results as a platform for sustained momentum: the company will press its global scale and digital capabilities to benefit patients, providers, and customers. The emphasis on a “discipline of execution” and a long-term view on portfolio leverage suggests management aims to translate operating leverage into durable earnings growth.

The call for deploying more than $1.85 billion of capital back to shareholders signals confidence that the current cash generation trajectory is sustainable. For rivals in the medical devices and sleep‑tech space, the message is clear: consistent cash returns paired with revenue growth and margin expansion remain a viable path to shareholder value, even as competition and inflationary pressures persist.

What this means for the sector and peers

ResMed’s FY2026 results underscore a broader theme in healthcare equipment: the combination of top-line growth, resilient demand for core devices, and a disciplined approach to capital allocation. The dividend uplift and the stated target for share repurchases may raise the bar for other companies’ capital-return policies, especially among firms balancing large capex needs with strong cash flow generation.

For sector peers, the takeaway is twofold. First, a credible plan to deploy cash—whether through buybacks, dividends, or strategic M&A—can be a meaningful driver of equity value when paired with improving margins. Second, the company’s emphasis on digital health capabilities suggests a continuing reallocation of resources toward software-enabled solutions and remote monitoring—areas that can augment traditional device care and potentially bolster long‑term revenue forecast visibility.

Operational notes and next steps

A webcast of ResMed’s conference call will be available at 4:30 p.m. ET on the day of release, inviting analysts to parse the quarter’s details and the fiscal 2027 outlook. The company’s strategic narrative—global scale, margin resilience, and increased capital returns—will likely be the focus, alongside any updates to EPS consensus expectations for the coming year.